6J9O image
Entry Detail
PDB ID:
6J9O
Title:
Crystal structure of a free scFv molecule from a group 2 influenza A viruses HA binding antibody AF4H1K1
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2019-01-23
Release Date:
2020-01-29
Method Details:
Experimental Method:
Resolution:
1.40 Å
R-Value Free:
0.19
R-Value Work:
0.17
R-Value Observed:
0.17
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Heavy chain of AF4H1K1 scFv
Chain IDs:A (auth: H)
Chain Length:130
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Light chain of AF4H1K1 scFv
Chain IDs:B (auth: L)
Chain Length:108
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Light chain modulates heavy chain conformation to change protection profile of monoclonal antibodies against influenza A viruses.
Cell Discov 5 21 21 (2019)
PMID: 30993000 DOI: 10.1038/s41421-019-0086-x

Abstact

The isolation of human monoclonal antibodies with broadly neutralizing breadth can provide a promising countermeasure for influenza A viruses infection. Most broadly neutralizing antibodies against influenza A viruses bind to the conserved stem region or the receptor-binding cavity of hemagglutinin and the interaction is dominated by the heavy chain. The light chain, however, contributes few or no direct contacts to the antigen. Here we report an H3-clade neutralizing human monoclonal antibody, AF4H1K1, which recognizes the hemagglutinin glycoproteins of all group 2 influenza A viruses. This human monoclonal antibody has been obtained through the screening by pairing different heavy and light chains from an H7N9-infected patient based on the next-generation sequencing technology. Further structural studies revealed that light chains modulate the neutralizing spectrum by affecting the local conformation of heavy chains, instead of direct interaction with the antigen. These findings provide important clues to understand the molecular basis of light chains in antigen recognition and to explore the strategies in particular of the use of light chain modification to develop broadly protective monoclonal antibodies against influenza A viruses and other emerging viruses.

Legend

Protein

Chemical

Disease

Primary Citation of related structures